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ABSTRACT
We used ciprofloxacin susceptibility as a phenotypic marker of community-associated methicillin-
resistant Staphylococcus aureus (CA-MRSA) in a London hospital collection of MRSA isolates from
inpatients, outpatients and primary-care clinics during 2000–2006. Four-hundred and fifty-eight
ciprofloxacin-susceptible (Cip-S) MRSA isolates were reported; antimicrobial susceptibility, staphylo-
coccal cassette chromosome mec (SCCmec) type, spa type and the presence of Panton–Valentine
leukocidin (PVL) genes were determined for all 194 surviving Cip-S MRSA isolates. Multilocus sequence
typing and pulsed-field gel electrophoresis were performed on representative isolates. Clinical and
epidemiological features of Cip-S MRSA infections were consistent with CA-MRSA, the incidence of
which increased markedly during the study period from 49 in 2000 to 102 in 2006. Most (82.0%) of the
surviving Cip-S MRSA isolates were SCCmec IV and 25.3% were PVL-positive. Considerable clonal
heterogeneity was noted among the recovered isolates, including the t044 ⁄ ST80-IV European clone and
the PVL-negative t127 ⁄ ST1-IV clone; PVL-positive t008 ⁄ ST8-IV (USA300) isolates were rare. Ciproflox-
acin susceptibility is a useful screening marker of CA-MRSA strains in London, which are more frequent
than previously thought and whose incidence is increasing.
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INTRODUCTION
Methicillin-resistant Staphylococcus aureus (MRSA)
is now widespread throughout the world and,
while prevalence varies from country to country,
most MRSA strains have been healthcare-associ-
ated (HA-MRSA) [1]. However, MRSA infections
are now emerging in patients without prior
contact with healthcare facilities [1,2]. These com-
munity-associated (CA)-MRSA strains tend to
affect individuals of all ages, are typically suscep-
tible to most non-b-lactam antimicrobials, have
diverse genetic backgrounds, carry small versions
(usually type IV or V) of staphylococcal cassette
chromosome mec (SCCmec, the mobile genetic
element carrying the methicillin-resistance gene,
mecA), often produce Panton–Valentine leukoci-
din (PVL), and may be highly virulent [2–7].
However, the definition of CA-MRSA remains
problematic because stable markers are lacking.
Although most CA-MRSA strains carry SCC
mec IV or SCCmec V, some have other or variant
SCCmec types [7] and HA-MRSA strains can carry
SCCmec IV [8,9]; not all CA-MRSA strains carry
the PVL genes [10–14]; and multiresistant
CA-MRSA strains have been reported [15]. Defi-
nitions of CA-MRSA based solely on epidemio-
logical data can overestimate the prevalence of
true CA-MRSA, since MRSA strains apparently
arising in the community can be HA-MRSA types
originating from hospitals [16]. CA-MRSA may
also cause outbreaks of healthcare-associated
infection [11,12], further confounding an epidemi-
ological definition. Thus, a combination of molec-
ular methods and epidemiological data is required
to differentiate CA-MRSA from HA-MRSA.
CA-MRSA strains were first noted in the early
1990s in Western Australia, [17] and then in the
late 1990s in North America [18]. CA-MRSA
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strains have since been reported from many
countries [1,2,19] and their prevalence has reached
alarming proportions in parts of the USA [20,21].
CA-MRSA strains have also been reported with
increasing frequency from European countries,
particularly from those with a low prevalence of
HA-MRSA [5,22]. However, despite a high prev-
alence of HA-MRSA, there have been few reports
of true CA-MRSA from the UK [8,23,24].
We conducted a retrospective analysis of stored
strains of MRSA isolated at our hospital to
determine whether the collection contained true
CA-MRSA. The great majority of HA-MRSA
strains in the UK are ciprofloxacin-resistant
(Cip-R) epidemic MRSA (EMRSA)-15 (ST22) or
EMRSA-16 (ST36) [25]. In contrast, the handful of
CA-MRSA strains reported to date in the UK have
been susceptible to most non-b-lactams, including
ciprofloxacin [23]; indeed, ciprofloxacin suscepti-
bility has been proposed as a phenotypic marker
of CA-MRSA in the UK [23,26]. Therefore, we
used ciprofloxacin susceptibility as a screening
marker to select isolates likely to be CA-MRSA
and employed a variety of molecular methods
combined with epidemiological data to further
characterize these strains in our collection.
METHODS
Guy’s and St Thomas’ NHS Foundation Trust (GSTT) is a 1200-
bed teaching and tertiary referral acute hospital trust located
on two sites in central London. GSTT has a collection of MRSA
isolates dating back to the 1990s, including MRSA isolates
from hospital patients and from those attending general
practitioners and other healthcare facilities in the local com-
munity; one isolate from each MRSA-positive patient is stored.
All isolates are stored at room temperature on nutrient agar
slopes, with the exception of blood isolates, which are stored
frozen in glycerol broth.
Selection of isolates, data collection and analysis
We analyzed epidemiological data on all patients who yielded
MRSA isolates (excluding screens) from 2000 to 2006. In some
patients, MRSA was isolated from multiple culture sites but a
single representative isolate was analyzed for typing and
microbiological characteristics. Our laboratory records of
hospital isolates contain information on patient age, culture
site, ward, medical specialty and antimicrobial susceptibility.
In addition, since 2003, the hospital infection control team has
prospectively classified each new inpatient MRSA episode as
hospital-acquired or present upon admission, on the basis of
previously reported epidemiological criteria [27].
Additional patient data were downloaded from the hospital
patient administration system for each ciprofloxacin-suscepti-
ble (Cip-S) MRSA isolate, including patient demographics,
admission and discharge dates, and codes for medical specialty,
diagnosis, procedure and health-related groups. Patients were
defined as having presumptive HA-MRSA if their MRSA-
positive specimen was collected >72 h after hospital admission
or <12 months after a previous inpatient stay. Infections in
patients with previous MRSA episodes (or with regular day
care, e.g. haematology and renal patients) were also classified
as HA-MRSA. Patients were defined as having presumptive
CA-MRSA if they had had no inpatient stay in the previous
12 months and their first MRSA-positive specimen was col-
lected in the community or within 72 h of hospital admission.
Statistical comparisons were made using the Mann–Whit-
ney or Kruskal–Wallace tests for continuous variables and the
chi-squared test for discrete variables using GraphPad Prism
version 5.00 (GraphPad Software, San Diego, CA, USA).
Microbiological analysis of surviving MRSA
Stored organisms were subcultured onto blood agar incubated
at 37C for 24 h. S. aureus was identified by standard methods
and tested for susceptibility to the following antimicrobial
agents by the British Society for Antimicrobial Chemotherapy
disk-diffusion method [28]: penicillin, methicillin, gentamicin,
neomycin, vancomycin, erythromycin, fusidic acid, tetracy-
cline, linezolid, rifampicin, mupirocin, trimethoprim and
ciprofloxacin. The methicillin MIC was determined by the
British Society for Antimicrobial Chemotherapy agar dilution
method [28].
DNA was extracted from S. aureus isolates by using the
ChargeSwitchTM gDNA mini-bacteria kit (Invitrogen Ltd,
Paisley, UK). The SCCmec type was determined by a multiplex
PCR reaction, which includes primers for mecA, as described
by Oliveria and de Lencastre [29]. SCCmec IV isolates were
subtyped using primers described by Holmes et al. [8].
S. aureus isolates were considered to be MRSA if mecA was
present. PVL genes were identified by the PCR reaction
described by Lina et al. [30]. spa typing was conducted as
described by Harmsen et al. [31]. spa types were clustered into
related clonal complexes (CCs) using the Based Upon Repeat
Patterns (BURP) algorithm in the Ridom StaphType software,
as described by Strommenger et al. [32], using a calculated cost
between members of £4 and excluding spa types shorter than
five repeats. The stringent clustering cost was chosen to
increase the resolution between spa CCs. A representative
isolate from each spa CC was typed by multilocus sequence
typing, as described by Enright et al. [33] and pulsed-field gel
electrophoresis (PFGE), as described by Holmes et al. [8].
RESULTS
Incidence of Cip-S MRSA
Four-hundred and fifty-eight (6.4%) of the 7146
unique patient MRSA isolates reported during
2000–2006 were Cip-S. The number of Cip-S
isolates reported increased year by year from 49
in 2000 to 102 in 2006 (Fig. 1). Although there was
a decrease in the total number of MRSA isolates
reported during 2003–2005, the proportion of Cip-
S MRSA isolates rose from 3.7% in 2000 to 13.2%
in 2006 (Fig. 1).
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Epidemiological comparison of Cip-S and Cip-R
MRSA
The features of the reported Cip-S and Cip-R
MRSA isolates are compared in Table 1. In com-
parison with Cip-R MRSA isolates, Cip-S MRSA
isolates affected younger patients (median age
44.8 vs. 68.5 years, p <0.0001), and were signifi-
cantly less likely to be resistant to erythromycin
(p <0.0001), gentamicin (p <0.0001) and mupiro-
cin (p <0.0001) but significantly more likely to be
resistant to fusidic acid (p <0.0001) and tetra-
cycline (p 0.0118). Cip-R MRSA isolates were
significantly more likely to be obtained from
adult inpatients, whereas Cip-S MRSA isolates
were more likely to be isolated from patients
attending accident and emergency wards, or
general practice and hospital specialties in which
MRSA is uncommon, such as paediatrics, obstet-
rics and gynaecology and genitourinary medicine.
Furthermore, 50.8% of the Cip-R MRSA isolates
were classified as hospital-acquired as compared
with only 26.3% of the Cip-S MRSA isolates
(p <0.0001). Cip-S MRSA isolates were signifi-
cantly more likely to be cultured from skin and
soft-tissue infections than Cip-R MRSA isolates
(64.1% vs. 45.6%, p <0.0001). MRSA isolates from
sites associated with HA-MRSA (such as respira-
tory sites, urine and intravascular catheter inser-
tion sites and tips) were significantly more likely
to be Cip-R, but there was no significant differ-
ence between the proportions of Cip-R and Cip-S
isolates from blood (data not shown). In contrast,
7.4% of the Cip-S MRSA isolates were cultured
from mucosal sites, as compared with 3.0% of the
Cip-R MRSA isolates (p <0.0001).
Characteristics of recovered Cip-S MRSA
One-hundred and ninety-four (42.2%) of the 458
reported Cip-S MRSA isolates were recovered
from storage. Although all 194 isolates were
mecA-positive, 23 (11.9%) were phenotypically
susceptible to methicillin according to either disk-
diffusion or agar dilution. The median methicillin
MIC was ‡16 mg ⁄L. One-hundred and fifty-nine
(82.0%) of the isolates were SCCmec IV and a
further 28 (14.4%) were non-typeable by the
multiplex PCR method used; only seven (3.6%)
of the isolates were SCCmec I, SCCmec II or
SCCmec III (Table 2).
Forty-nine (25.3%) of the Cip-S isolates were
PVL-positive; 12 (11.8%) of the 102 from 2000 to
2004 were PVL-positive, as compared with 37
(40.2%) of 92 from 2005 to 2006 (p <0.0001)
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Fig. 1. Total number of ciprofloxacin-susceptible (Cip-S)
methicillin-resistant Staphylococcus aureus (MRSA) isolates
reported by year (bars) and the proportion of 458 Cip-S
MRSA isolates among all 7146 unique patient MRSA
isolates reported by year (line), 2000–2006.
Table 1. Features of ciprofloxacin-resistant (Cip-R)
methicillin-resistant Staphylococcus aureus (MRSA) com-
pared with ciprofloxacin-susceptible (Cip-S) MRSA
reported at Guy’s and St Thomas’ NHS Foundation Trust,
2000–2006 (percentage of total in parentheses unless
otherwise stated).
Cip-R MRSA Cip-S MRSA p valuea
Total number reported 6688 458 –
Median patient age (years) 68.5 44.8 <0.0001b
Antimicrobial resistancec
Erythromycin 5566 (89.4) 230 (51.7) <0.0001
Gentamicin 1718 (25.8) 28 (6.1) <0.0001
Fusidic acid 465 (7.5) 192 (43.1) <0.0001
Tetracycline 366 (11.5) 51 (16.6) 0.0118
Mupirocin 717 (10.9) 11 (2.5) <0.0001
Collection location
Adult inpatient 5024 (75.1) 205 (44.8) <0.0001
Paediatric inpatient 113 (1.7) 33 (7.2) <0.0001
Accident and emergency 290 (4.3) 69 (15.1) <0.0001
General practitioner 1105 (16.5) 116 (25.3) <0.0001
Outpatient clinic 124 (1.9) 16 (3.5) 0.0248
Genitourinary medicine 1 (0.0) 9 (2.0) <0.0001
Obstetrics, gynaecology
and maternity
31 (0.5) 10 (2.2) <0.0001
Infection classificationd
Hospital acquisition 1259 (50.8) 56 (26.3) <0.0001
Present on admission 1012 (40.8) 144 (67.6) <0.0001
Previous positive 208 (8.4) 13 (6.1) 0.0007
Specimene
Skin and soft tissue infection 8799 (45.6) 449 (64.1) <0.0001
Respiratory 2971 (15.5) 77 (11.0) 0.0016
Urine 815 (4.2) 13 (1.9) 0.0027
Mucosal 572 (3.0) 52 (7.4) <0.0001
Invasive ⁄ line ⁄ tipf 2536 (13.2) 53 (7.6) <0.0001
Other 3535 (18.4) 56 (8.0) <0.0001
ap values calculated using chi-squared tests of 2 · 2 contingency tables unless
otherwise stated.
bp value calculated using a two-tailed Mann–Whitney test.
cNot all antimicrobial agents were tested for all reported isolates; percentages
represent the number that were positive as a proportion of the total tested.
dFrom 2003, infections were classified as ‘hospital-acquired’, ‘present upon admis-
sion’ or ‘previously positive’ if the patient had had a previous MRSA episode. Two
thousand four hundred and seventy-nine Cip-R and 144 Cip-S infections were
classified; classification data were not available for many of the outpatients.
eCip-R MRSA was cultured from 19 228 separate sites and Cip-S MRSA was
cultured from 700 separate sites.
fThis group includes blood cultures, isolates from normally sterile sites, e.g. bone,
and from lines and tips.
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(Fig. 1). Among the 37 PVL-positive Cip-S MRSA
isolates from 2005 to 2006, there were 21 different
spa types grouped into three spa CCs and 12
singleton lineages by BURP analysis; no single
clone was responsible for the increase in PVL-
positive MRSA in the latter years of the study.
Sixty-five distinct spa types were identified
among the 194 Cip-S MRSA isolates, including
previously described CA-MRSA lineages, and
are summarized in Table 2. t127 was the most
common spa type; it was ST1 and usually
PVL-negative, consistent with Western Australian
(WA)-MRSA-1, which has a PFGE profile that is
closely related to that of USA-400 [10]. Six t127
isolates were PVL-positive and showed consider-
able phenotypic and genotypic heterogeneity,
exhibiting five distinct antibiograms and five
distinct SCCmec types related to type IV (data
not shown). Drug or alcohol abuse was noted in
the medical records of 39.4% of the 72 t127
patients (Table 2), and 47.2% were homeless or
living in temporary sheltered accommodation;
12.5% of the patients shared the same homeless
shelter (data not shown). Although 30 (41.7%) of
the t127 infections were classified as healthcare-
associated, 21 of these had unusual features: two
were in maternity wards and six were from
paediatric wards (Table 2); six patients were
injecting drug-users with inpatient healthcare
contact and nine of the patients were homeless
or living in temporary sheltered accommodation
(data not shown).
Twelve (6.2%) of the isolates were t044; a
representative isolate was ST80 and had a PFGE
profile consistent with that of the European clone.
Nine (75.0%) of the t044 isolates were classified as
community-associated and the other three were
atypical, isolated from healthcare-associated
infections (infected Caesarian section, bone cul-
ture from a paediatric patient, abscess in an
outpatient with previous multiple sclerosis-
related inpatient stays (data not shown)).
In contrast, the 12 t022 isolates were consistent
with EMRSA-15; a representative isolate was ST22
and had a common UK EMRSA-15 PFGE profile
[25] (data not shown). All 12 isolates were PVL-
Table 2. Features of 194 ciprofloxacin-susceptible methicillin-resistant Staphylococcus aureus (MRSA) isolates reported at
Guy’s and St Thomas’ NHS Foundation Trust, 2000–2006 (percentage of total in each spa type in parentheses unless
otherwise stated).
t127 (%) t044 (%) t022 (%) t002 (%) t008 (%) Other (%) Total (%) p valuea
Total 72 (37.1) 12 (6.2) 12 (6.2) 11 (5.7) 7 (3.6) 80 (41.2) 194 (100.0) –
MLSTb 1 80 22 5 8 – – –
SCCmecc type
I, II or III 2 (2.8) 0 0 0 0 5 (6.3) 7 (3.6) 0.6508
Non-typeable 9 (12.5) 0 0 2 (18.2) 1 (14.3) 16 (20.0) 28 (14.4) 0.2693
IV 61 (84.7) 12 (100.0) 12 (100.0) 9 (81.8) 6 (85.7) 59 (73.8) 159 (82.0) 0.0953
PVLd 6 (8.3) 12 (100.0) 0 0 4 (57.1) 27 (33.8) 49 (25.3) <0.0001
Antimicrobial resistance
Erythromycin 37 (51.4) 6 (50.0) 1 (8.3) 1 (9.1) 0 22 (27.5) 67 (34.5) 0.0004
Fusidic acid 55 (76.4) 6 (50.0) 0 1 (9.1) 2 (28.6) 18 (22.5) 82 (42.3) <0.0001
Tetracycline 3 (4.2) 5 (41.7) 0 1 (9.1) 1 (14.3) 16 (20.0) 26 (13.4) 0.0023
Neomycin 1 (1.4) 11 (91.7) 0 1 (9.1) 1 (14.3) 16 (20.0) 30 (15.5) <0.0001
Risk-factors
Drug or alcohol abuse 28 (39.4) 0 1 (8.3) 2 (18.2) 1 (14.3) 5 (6.6) 37 (22.2) <0.0001
Neoplasm 1 (1.4) 0 5 (41.7) 1 (9.1) 0 8 (10.5) 15 (9.0) 0.0001
Collection location
Inpatient 31 (43.1) 4 (33.3) 12 (100.0) 4 (36.4) 1 (14.3) 39 (48.7) 91 (46.9) 0.0024
Outpatient or A&Ee 41 (56.9) 8 (66.7) 0 7 (63.6) 6 (85.7) 41 (51.3) 103 (53.1) 0.0024
Specimen
SSTIf 70 (60.3) 12 (75.0) 11 (45.8) 11 (78.6) 6 (66.7) 66 (62.9) 176 (62.0) 0.3375
SSTI—abscess 7 (6.0) 4 (25.0) 0 2 (14.3) 3 (33.3) 6 (5.7) 22 (7.7) 0.0021
Respiratory 12 (10.3) 0 7 (29.2) 0 0 10 (9.5) 29 (10.2) 0.0163
Invasive and line or tip 15 (12.9) 1 (6.3) 2 (8.3) 2 (14.3) 1 (11.1) 10 (9.5) 31 (10.9) 0.9265
Infection classificationg
Healthcare-associated 30 (41.7) 3 (25.0) 12 (100.0) 5 (45.5) 0 39 (48.8) 88 (45.4) 0.0019
Community-associated 41 (56.9) 9 (75.0) 0 6 (54.5) 7 (100.0) 37 (46.3) 101 (52.1) 0.0013
ap values calculated using chi-squared tests of 2 · 6 contingency tables unless otherwise stated. p values <0.05 highlighted in bold.
bMulti-locus sequence type; the MLST type of one representative isolate from the most common spa type within each spa clonal complex was determined.
cStaphylococcal cassette chromosome mec.
dPanton–Valentine leukocidin genes.
eAccident and emergency. This category includes isolates from genitourinary medicine and obstetrics and gynaecology.
fSkin and soft-tissue infection.
gPatients were defined as having presumptive healthcare-associated MRSA if their MRSA-positive specimen was collected >72 h after hospital admission or <12 months after
a previous inpatient stay. Infections in patients with previous MRSA episodes (or with regular day care, e.g. haematology and renal patients) were also classified as healthcare-
associated MRSA. Patients were defined as having presumptive community-associated MRSA if they had had no inpatient stay in the previous 12 months and their first
MRSA-positive specimen was collected in the community or within 72 h of hospital admission.
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negative and contained SCCmec IV; all 12 were
healthcare-associated. BURP clustering included
seven further Cip-S MRSA isolates in a spa CC
with the t022 isolates, which were all PVL-
negative and had similar healthcare-associated
characteristics (data not shown).
Seven of the 194 isolates were t008. A repre-
sentative isolate was ST8 and these isolates were
associated with abscess formation, PVL produc-
tion and community-associated infections. They
showed considerable heterogeneity: four were
PVL-positive, and there were five different anti-
biograms and three different SCCmec IV-related
types (Table 2).
t002 is a common spa type that includes a range
of healthcare-associated clones. Eleven diverse
isolates of t002 were associated with both hospital
and community infections.
Sixty different spa types were reported among
the 80 remaining isolates, 33.8% of which were
PVL-positive. The PVL-positive isolates were
diverse, with 24 distinct spa types clustering
into five spa CCs and eight singleton lineages.
Recognized CA-MRSA clones that occurred
infrequently in our collection included four
PVL-positive ST59 isolates (two t437 and two
t216 types), three of which occurred in 2006, and
individual occurrences of PVL-positive USA-
400 ⁄ ST1 t128 and t311 types.
DISCUSSION
HA-MRSA is common in the UK [1] but reports
of CA-MRSA in the UK have been rare. In 2005,
the national Staphylococcus reference laboratory
for England and Wales reported that only 100
CA-MRSA isolates had been referred in the previ-
ous 3 years [23] and there have been only sporadic
reports since then [8,13,24,34,35], including two
healthcare-associated outbreaks in 2006 [11,26].
The epidemiological and microbiological char-
acteristics of Cip-S MRSA reported at GSTT from
2000 to 2006 were more consistent with
CA-MRSA than with HA-MRSA (Table 1). As
compared with Cip-R MRSA isolates, Cip-S
MRSA isolates were associated with younger
patients [6], resistance to fewer antimicrobial
agents [7], low-level expression of methicillin
resistance [7], presentation in outpatient settings
or hospital specialties in which MRSA is uncom-
mon [12] and skin and soft-tissue infections,
especially abscesses [2,5].
We observed marked increases during 2000–
2006 in both the number and proportion of Cip-S
MRSA isolates, which is consistent with other
reports from the UK and other countries
[2,5,14,22,34,36]. For example, a recent retrospec-
tive analysis of the UK General Practice Research
Database by Schneider-Lindner et al. [36] found
that the incidence of epidemiologically defined
presumptive CA-MRSA increased by 45.8% from
332 cases in 2000 to 484 cases in 2004 [36]. We also
noted a marked increase in the frequency of PVL-
positive MRSA isolates among our recovered Cip-
S MRSA isolates in the latter years of our study.
PVL has been proposed as a virulence determi-
nant in CA-MRSA [3] and there is a strong
epidemiological association between PVL pro-
duction and successful CA-MRSA lineages [5,7].
However, not all CA-MRSA lineages carry PVL
[10–12] and certain studies have questioned the
value of PVL as a virulence determinant [13,37] or
universal marker of CA-MRSA [14]. The propor-
tionate increase in PVL-producing isolates in the
latter years of our study could be explained by
loss of bacteriophage-mediated PVL genes from
older isolates stored at room temperature on
slopes; however, this is unlikely because the
proportion of a given spa type that was PVL-
positive tended to remain constant (data not
shown).
The increase in the frequency of PVL-positive
MRSA was not due to the emergence of a
dominant clone. Clonal heterogeneity is a feature
of CA-MRSA, with many clones circulating con-
currently in the same country [7,10,23], presum-
ably resulting from repeated de novo insertion of
SCCmec into multiple S. aureus lineages. How-
ever, certain clones have established themselves
as the predominant cause of CA-MRSA infection
in certain localities, e.g. USA-300 in the USA
[19,20,38] and the ST80 clone in continental
Europe [5,19,22]. We noted clonal heterogeneity
throughout the study period with representatives
of ST80, ST59, ST8 and both PVL-positive and
PVL-negative ST1 CA-MRSA lineages but rarely
USA-300, USA-400 or the successful ST30
CA-MRSA clone [4].
The most common clone identified in our study
was PVL-negative ST1 t127, which was closely
associated with injecting drug-users and home-
less people living in sheltered accommodation.
Nine (12.5%) of the patients with t127 MRSA
shared the same homeless shelter in the same
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2-year period, which could be evidence of a focus
of community transmission [39]. The ST1 t127
CA-MRSA clone has been reported as a cause of
CA-MRSA infection in injecting drug-users in the
UK [40].
Our study has several limitations. First, we
collected isolates from a single centre, although
the geographical distribution of our isolates from
primary care was wide. Second, our data collec-
tion was retrospective, which resulted in incom-
plete clinical information. For example, infection
control classification information was only avail-
able from 2003 to 2006. Third, ciprofloxacin
susceptibility is an imperfect marker for CA-
MRSA; for example, ciprofloxacin-susceptible
EMRSA-15 has been reported at low frequency
in the UK, and was responsible for a small
outbreak of MRSA on our neonatal unit in 2006
[9]. Fourth, we were only able to recover 42.2% of
the reported Cip-S MRSA isolates from storage, so
clones with poor survival characteristics may be
under-represented. Fifth, with the exception of
t127, the number of isolates with the same spa
type was small, so it is difficult to draw reliable
conclusions about spa type-related associations.
Despite these limitations, to the best of our
knowledge this is the first systematic study of CA-
MRSA in the UK. We conclude that ciprofloxacin
susceptibility is a useful phenotypic tool to aid in
the identification of CA-MRSA in our locality. In a
collection of MRSA isolates from inpatients,
outpatients and primary-care clinics, we found
that the incidence of CA-MRSA increased during
2000–2006 and isolates displayed considerable
clonal heterogeneity. We plan prospective
studies to define more clearly the prevalence of
CA-MRSA in the community served by our
hospitals.
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